Received Aug 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | 3046734 | IM |
numbness and tingling in his fingers started this morning; numbness and tingling in his fingers started this morning; This spontaneous case was reported by an other health care professional and describes the occurrence of HYPOAESTHESIA (numbness and tingling in his fingers started this morning) and PARAESTHESIA (numbness and tingling in his fingers started this morning) in a 73-year-old male patient who received mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (batch no. 3046734) for COVID-19 prophylaxis. Concurrent medical conditions included Arthritis. Concomitant products included Cyclobenzaprine hydrochloride (Cyclobenzaprine), Duloxetine hydrochloride (Duloxetine), Tamsulosin hydrochloride (Tamsulosin), Tadalafil and Tadalafil (Cialis) for an unknown indication. On 31-Jul-2025, the patient received dose of mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Intramuscular use) .5 milliliter. On 01-Aug-2025, the patient experienced HYPOAESTHESIA (numbness and tingling in his fingers started this morning) and PARAESTHESIA (numbness and tingling in his fingers started this morning). At the time of the report, HYPOAESTHESIA (numbness and tingling in his fingers started this morning) and PARAESTHESIA (numbness and tingling in his fingers started this morning) had not resolved. For mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Intramuscular use), the reporter did not provide any causality assessments. The HCP was not aware of any other vaccines administered 4 weeks prior to Spikevax. The patient received most of his vaccines and had some pain medications at the pharmacy. The HCP enquired about a side effect one of their patients experienced after receiving the COVID-19 vaccine the previous day. On the morning of 01-Aug-2025, a patient contacted the pharmacy to report experiencing numbness in their fingers following administration of the COVID-19 vaccine the previous day. The pharmacist spoke with the patient over the phone. The HCP believed the numbness and tingling in his fingers began that same morning and had not yet resolved. After conducting some research, the HCP was unable to find substantial information on this side effect and sought to learn whether similar cases had been reported. She was particularly interested in understanding the outcomes of those cases and whether there is a typical timeline for resolution. It was unknown if the patient experienced any additional symptoms or events.
Arthritis
Cyclobenzaprine; Duloxetine; Tamsulosin; Tadalafil; Cialis